A431 |
Dermatoma cancer |
A-549 |
Lung cancer |
AChE |
Acetylcholinesterase |
B16F10 |
Melanogenesis activity |
BEN-MEN-1 |
Meningioma |
BGC-823 |
Human gastric carcinoma |
CAL-27 |
Head and neck squamous cell carcinomas |
CCF-STTG1 |
Astrocytoma |
CHG-5 |
Glioma |
CI |
Confidence intervals |
Detroit-562 |
Head and neck squamous cell carcinomas |
ED50
|
Median effective dose |
F.sp. |
Forma specialis, abbreviated f. sp., is an informal taxonomic grouping allowed by the International Code of Nomenclature for algae, fungi, and plants |
HCT 116 |
Human colorectal carcinoma |
HeLa |
Human Gastric cancer |
Hep-2 |
Head and neck squamous cell carcinomas |
HepG2 |
Human hepatocellular |
HIF-α |
Hypoxia-inducible factor |
HL-60 |
Human myeloid leukemia |
HS-1 |
Dermatona cancer |
HS-4 |
Dermatona cancer |
HT-29 |
Human colorectal carcinoma |
IC50
|
Half maximal inhibitory concentration |
ID50
|
Median infective dose |
IL-1β |
Interleukin 1 beta |
LNCaP |
Human prostate carcinoma |
M663 |
Osteosarcoma cells |
MCF-7 |
Human breast cancer |
MDA-MB-231 |
Human breast adenocarcinoma |
MG-63 |
Osteosarcoma cells |
MIAs |
Terpenoid indole compounds |
MIAs |
Monoterpenoid indole compounds |
MIC |
Minimum inhibitory concentration |
NF-kB |
Nuclear factor k-light-chain-enhancer of activated B cells |
NO |
Nitric oxide |
PANC-1 |
Pancreatic cancer |
PC-3 |
Human prostate carcinoma |
PGE2 |
Prostaglandin E2 |
SAOS-2 |
Osteosarcoma cell lines |
SCC-PKU |
Head and neck squamous cell carcinomas |
SCL-1 |
Head and neck squamous cell carcinomas |
SGC-7901 |
Gastric cancer |
SHG-44 |
Human glioma cancer |
SK-BR-3 |
Human breast cancer |
SK-MEL-2 |
Human skin cancer |
SMMC-7721 |
Hepatocellular carcinoma |
SOSP-9607 |
Human Osteosarcoma cell lines |
SW480 |
Human Colon cancer |
TCA-83 |
Head and neck squamous cell carcinomas |
TNF-α |
Tumor necrosis factor-α |
U251 |
Human glioma cancer |
U2-OS |
Osteosarcoma cell lines |
UMSCC-1 |
Head and neck squamous cell carcinomas |